Results 31 to 40 of about 37,394 (238)

Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group. [PDF]

Circ Heart Fail, 2022
Maurer MS, Dunnmon P, Fontana M, Quarta CC, Prasad K, Witteles RM, Rapezzi C, Signorovitch J, Lousada I, Merlini G.   +9 more
europepmc   +2 more sources

The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis. [PDF]

Amyloid, 2020
Angel-Korman A, Jaberi A, Sanchorawala V, Havasi A.   +3 more
europepmc   +2 more sources

Pharmacological stabilization of the native state of full-length immunoglobulin light chains to treat light chain amyloidosis.

Current Opinion in Chemical Biology, 2023
Immunoglobulin light chain amyloidosis (AL) is a cancer of plasma cells that secrete unstable full-length immunoglobulin light chains. These light chains misfold and aggregate, often with aberrant endoproteolysis, leading to organ toxicity.
N. Yan, G. Morgan, H. Petrassi, I. Wilson, J. Kelly   +4 more
semanticscholar   +1 more source

Syndrome in Question [PDF]

Anais Brasileiros de Dermatologia, 2015
Immunoglobulin light chain amyloidosis is the most common acquired systemic amyloidosis. Its presentation is often insidious and progressive, which may delay diagnosis.
Han MA, Meilan Chen, Juan Li, Ying Li, Shu Qiu   +4 more
doaj   +1 more source

Immunoglobulin light chain amyloidosis presenting as Budd-Chiari syndrome. [PDF]

Hepatol Forum, 2021
Ozercan M, Eser I, Kiremitci S, Peynircioglu B, Karayalcin S, Idilman R.   +5 more
europepmc   +3 more sources

Strong positive light chain immunostaining in a patient with transthyretin amyloidosis

Hematology, 2023
The two most common systemic amyloidosis types are immunoglobulin light chain (AL) and amyloid transthyretin (ATTR) amyloidosis, in which the precursor proteins responsible for amyloidosis are light chain and transthyretin, respectively.
Jiao Chen, Haifei Chen, Lingyun Zhou, Danbo Liu, Fang Du, Hongxian Xiang   +5 more
doaj   +1 more source

Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis.

PLoS ONE, 2020
Immunoglobulin light chain amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis is caused by a misfolded light chain produced by a clonal population of plasma cells.
Elaine C Chen, Samuel Rubinstein, Cinque Soto, Robin G Bombardi, Samuel B Day, Luke Myers, Alexey Zaytsev, Mahsa Majedi, R Frank Cornell, James E Crowe   +9 more
doaj   +1 more source

Inhibition by small-molecule ligands of formation of amyloid fibrils of an immunoglobulin light chain variable domain. [PDF]

, 2015
Overproduction of immunoglobulin light chains leads to systemic amyloidosis, a lethal disease characterized by the formation of amyloid fibrils in patients' tissues. Excess light chains are in equilibrium between dimers and less stable monomers which can
Brumshtein, Boris, Cascio, Duilio, Eisenberg, David S, Esswein, Shannon R, Ly, Alan T, Phillips, Martin L, Salwinski, Lukasz, Sawaya, Michael R   +7 more
core   +1 more source

AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; a case mimicking AHL amyloidosis

BMC Nephrology, 2018
Background Immunoglobulin heavy-and-light-chain amyloidosis (AHL amyloidosis) is a newly established disease entity where both the immunoglobulin heavy-chain and light-chain compose amyloid fibrils. The immunoglobulins responsible for the amyloid fibrils
Shun Manabe, Chihiro Iwasaki, Michiyasu Hatano, Fuyuki Kametani, Masahide Yazaki, Kosaku Nitta, Michio Nagata   +6 more
doaj   +1 more source

Idiopathic membranous nephropathy with renal amyloidosis: A case report

Frontiers in Medicine, 2022
BackgroundImmunoglobulin light chain amyloidosis is a clonal, non-proliferative plasma cell disorder, in which fragments of immunoglobulin light chain are deposited in tissues.
Yue Wang, Xueyao Wang, Jinyu Yu, Shan Wu, Zhonggao Xu, Weixia Sun   +5 more
doaj   +1 more source